Blood pressure control in hypertensive patients in Irish primary care practices.
In Ireland, cardiovascular disease is a major cause of death. However, blood pressure (BP) goal achievement is unsatisfactory. The authors aimed to document BP control and increase awareness. A total of 1534 patients were enrolled in the study, with a mean age of 64.7+/-11.9 years (53.8% women). Duration of hypertension was 8.7+/-7.7 years, and 14.6% had diabetes, 13.8% had coronary artery disease, and 40.5% were taking antihypertensive monotherapy. beta-Blockers (39.8%), angiotensin-converting enzyme inhibitors (32.2%), and angiotensin receptor blockers (22.0%) were prescribed most frequently. Mean BP was 136.0+/-6.1 mm Hg/89.5+/-5.0 mm Hg in nondiabetic patients (48.6% <140/90 mm Hg) and 131.0+/-7.4 mm Hg/81.7+/-4.6 mm Hg in diabetic patients (16.7% <130/80 mm Hg). Diet, exercise, and lifestyle modifications (63.5%) were frequently recommended. Increased patient awareness and compliance together with the adherence of physicians to current guidelines and greater willingness to take action in patients with uncontrolled hypertension should help in improving BP control and thus reduce cardiovascular risk.
Buckley
Brendan
B
European Centre for Clinical Trials in Rare Diseases, University College Cork, Cork, Ireland. b.buckley@ucc.ie
Shanahan
Eamonn
E
Colwell
Niall
N
Turgonyi
Eva
E
Bramlage
Peter
P
Perry
Ivan J
IJ
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000502:physiology*; D003131:Combined Modality Therapy; D004035:Diet Therapy; D005081:Exercise Therapy; D005260:Female; D006306:Health Surveys; D006801:Humans; D006973:Hypertension / Q000453:epidemiology / Q000503:physiopathology* / Q000628:therapy*; D007494:Ireland / Q000453:epidemiology; D008019:Life Style; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011320:Primary Health Care; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents
BMJ. 2001 Mar 3;322(7285):531-6
11230071
Ann Intern Med. 2001 Nov 6;135(9):825-34
11694107
Circulation. 2006 Jan 17;113(2):213-21
16391156
BMJ. 2004 Mar 13;328(7440):634-40
15016698
Arch Intern Med. 2002 Feb 25;162(4):413-20
11863473
J Clin Hypertens (Greenwich). 2009 Jan;11(1):1-4
19125851
Ir Med J. 2002 Nov-Dec;95(10):298-301
12542011
Lancet. 2002 Dec 14;360(9349):1903-13
12493255
J Hum Hypertens. 2006 Dec;20(12):917-22
16988753
Ger Med Sci. 2006 Oct 09;4:Doc07
19675698
J Hypertens. 2004 Mar;22(3):479-86
15076152
Curr Med Res Opin. 2007 Apr;23(4):783-91
17407635
J Hypertens. 2004 Jan;22(1):11-9
15106785
J Epidemiol Community Health. 2006 Apr;60(4):322-7
16537349
Blood Press Monit. 2002 Apr;7(2):135-42
12048432
Eur Heart J. 1995 Jun;16(6):752-60
7588918
JAMA. 2003 May 14;289(18):2363-9
12746359
J Clin Hypertens (Greenwich). 2007 May;9(5):316-23
17485966
J Hypertens. 2007 Jun;25(6):1105-87
17563527
J Am Coll Cardiol. 2007 Aug 14;50(7):563-72
17692739
JAMA. 2003 May 21;289(19):2560-72
12748199
Lancet. 2006 May 27;367(9524):1747-57
16731270
Am J Hypertens. 1998 Apr;11(4 Pt 1):445-53
9607383